Enliven <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Reports Promising ELVN-001 Results in CML Patients With Atypical Fusion Transcripts
Enliven Therapeutics Inc. announced that it will present preliminary clinical data from the ongoing ENABLE Phase 1a/1b trial of ELVN-001, a selective active site inhibitor of BCR::ABL1, in chronic myeloid leukemia (CML) patients with atypical fusion transcripts at the 67th Annual American Society of Hematology $(ASH)$ 2025 Annual Meeting. The presentation is scheduled for December 7, 2025, in Orlando, Florida. According to the company, ELVN-001 demonstrated encouraging anti-CML activity in a heavily pretreated patient population, including those with the e13a3 fusion transcript, which is resistant to certain tyrosine kinase inhibitors. Detailed data will be available following the presentation on Enliven Therapeutics' website.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA13119) on November 03, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。